Our Pipeline

Aceragen expects to initiate 3 clinical studies in 2022

Pre-clinical Phase 1 Phase 2 Phase 3
ACG-801
(acid ceramidase)
Farber disease
Initiation 2022
ACG-701
(sodium fusidate)
Melioidosis
Initiation 2022
Cystic fibrosis
(PEx treatment)
Initiation 2022
ACG-301
(DnaK inhibitor)
Oncology
ACG-401
(leptin receptor inhibitor)
Oncology

Expanded Access

Aceragen intends to execute clinical programs for its lead investigational products, ACG-701 and ACG-801. Please watch this site for updates on our progress toward this goal or you can contact us directly at info@aceragen.com. Under section 561(b) of the FD&C Act, Aceragen’s medical staff and advisors will evaluate Expanded Access requests following review of Phase III clinical data.  All such requests should be initiated via the designated contact form.